Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Korro Bio, Inc. is a biotechnology company focused on developing precision genetic medicines using RNA editing technologies. The company operates within the biopharmaceutical and genetic medicine industries, with a core emphasis on RNA-based therapeutics designed to precisely modify RNA transcripts without altering underlying DNA. Its primary business activity is the discovery and development of RNA editing therapies targeting genetically defined diseases, particularly those driven by single-base mutations.
Korro’s platform is centered on its proprietary RNA Editing Oligonucleotide (REO™) technology, which leverages endogenous ADAR enzymes to correct disease-causing RNA variants. The company’s strategic positioning lies in its ability to pursue highly specific, potentially repeat-dosable therapies with reduced risk of permanent genomic alteration. Korro was founded in 2018 and advanced from early academic research into a publicly traded company following its initial public offering in 2021, using proceeds to expand its pipeline and platform capabilities.
Business Operations
Korro operates as a single-reporting-segment biotechnology company, generating no commercial product revenue and relying primarily on equity financing and collaboration-related funding to support operations. Its core activities include research, preclinical development, and early-stage clinical advancement of RNA editing therapeutics. The company’s lead development programs target rare and genetically defined diseases, with a primary focus on alpha-1 antitrypsin deficiency (AATD).
The company’s operations are primarily domestic, with research and development conducted in the United States. Korro controls its proprietary REO™ platform, along with associated intellectual property covering RNA editing chemistry, delivery, and targeting strategies. While Korro has engaged in scientific collaborations and academic partnerships, it does not currently report large-scale commercial joint ventures or revenue-generating licensing agreements.
Strategic Position & Investments
Korro’s strategic direction centers on advancing its lead RNA editing programs into clinical development while expanding the applicability of its platform across additional disease targets. The company has invested heavily in platform optimization, delivery technologies, and translational research to support future pipeline expansion beyond its initial liver-focused indications.
The company has not completed major acquisitions and instead emphasizes internal R&D investment. Its pipeline development strategy prioritizes rare diseases with clear genetic drivers, enabling smaller, more targeted clinical trials. Korro also maintains flexibility to pursue future strategic partnerships or licensing arrangements to support late-stage development and commercialization.
Geographic Footprint
Korro Bio is headquartered in the United States, with its principal offices and laboratory facilities located in Cambridge, Massachusetts, a major biotechnology hub. The company’s operational footprint is primarily concentrated in North America, where it conducts research, development, and corporate functions.
While Korro does not maintain significant physical operations outside the U.S., its therapeutic ambitions are global in scope. Any future clinical trials, regulatory submissions, or commercialization efforts are expected to involve international markets, particularly in regions with established regulatory frameworks for genetic medicines.
Leadership & Governance
Korro is led by an executive team with experience in RNA biology, drug development, and biotechnology company building. The leadership emphasizes scientific rigor, precision medicine, and disciplined capital allocation as core elements of its strategic vision.
Key executives include:
- Ram Aiyar – President and Chief Executive Officer
- Nancy MacDonald – Chief Financial Officer
- Mark W. Moore, Ph.D. – Chief Scientific Officer
- Michael K. Kauffman, M.D., Ph.D. – Chief Medical Officer
The company is governed by a board of directors with backgrounds spanning biotechnology, finance, and pharmaceutical development, providing oversight of strategy, risk management, and long-term value creation.